ELOVL6-IN-4

Cat. No.:	HY-152947
CAS No.:	1170321-92-2
Molecular Formula:	$C_{20}H_{20}F_3N_3O_3S$
Molecular Weight:	439.45
Target:	Others
Pathway:	Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (227.56 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2756 mL	11.3779 mL	22.7557 mL
	5 mM	0.4551 mL	2.2756 mL	4.5511 mL
	10 mM	0.2276 mL	1.1378 mL	2.2756 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (5.69 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.69 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (5.69 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

ELOVL6-IN-4 is a potent, selective, and orally active long chain fatty acid elongase 6 (ELOVL6) inhibitor with IC_{50}s of 79 nM and 94 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-4 shows excellent selectivity over the other human ELOVL subtypes (ELOVL1, -2, -3, and -5) and mouse ELOVL3[1].

In Vitro

ELOVL6-IN-4 (compound 1w) potently reduced the elongation index in mouse hepatocyte cells H2.35, with an IC_{50} of 30 nM.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ELOVL6-IN-4 (compound 1w; 1-10 mg/kg; oral administration; once) potently and dose-dependently suppresses the elongation index in the liver in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice[1]
Dosage:	1 mg/kg, 3 mg/kg, and 10 mg/kg
Administration:	Oral administration; once
Result:	Potently and dose-dependently suppressed the elongation index in the liver in mice.

REFERENCES

[1]. Tsuyoshi Nagase, et al. Synthesis and biological evaluation of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. J Med Chem. 2009 Jul 23;52(14):4111-4.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA